StockNews.AI
XBIO
StockNews.AI
146 days

Xenetic Biosciences, Inc. Announces Entry by Collaboration Partner into a Clinical Study Agreement to Advance Development of DNase Platform for the Treatment of Relapsed/Refractory Osteosarcoma and Ewing Sarcoma

1. Xenetic Partners with PeriNess for clinical study on XBIO-015. 2. Study targets relapsed osteosarcoma and Ewing sarcoma patients.

2m saved
Insight
Article

FAQ

Why Bullish?

The collaboration with PeriNess and exploratory study can enhance XBIO's market presence. Historical preclinical and clinical collaborations often lead to positive stock performance.

How important is it?

The clinical study's outcome is pivotal for XBIO's pipeline and may dictate future valuations, particularly in niche cancer treatments.

Why Long Term?

Successful study outcomes can drive long-term growth and revenue opportunities for XBIO, similar to previous biotech collaborations yielding drugs approved for market.

Related Companies

PFEAMGNABT
Investigator initiated study with collaboration partner, PeriNess, to be conducted at the Tel-Aviv Sourasky Medical Center FRAMINGHAM, MA / ACCESS Newswire / March 26, 2025 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers, today announced that its collaboration partner, PeriNess Ltd. ("PeriNess"), has entered into a Clinical Study Agreement (the "Agreement") to support an exploratory clinical study of Xenetic's systemic DNase I candidate, XBIO-015, in patients with relapsed/refractory osteosarcoma and Ewing sarcoma.

Related News